Knight Therapeutics Inc. KHTRF
Set alert
At close · Oct 30
- YTD
- +85.98%
- 1 year
- +95.88%
- Open
- 8.12
- Prev close
- 8.24
- Mkt cap
- 794.69M
- Vol
- 100
- Avg vol
- 2.10K
- EPS
- 0.11
- P/E
- 73.55
More statistics
- Low
- 8.12
- High
- 8.12
News
2 months ago marketbeat.com
Knight Therapeutics Q2 Earnings Call Highlights
Knight Therapeutics TSE: GUD reported record results for the first six months of 2026 and raised its full-year outlook, citing growth in its promoted products, contributions from recent launches and…
4 months ago globenewswire.com
Knight Therapeutics Announces Repayment of Revolving Credit Facility
MONTREAL, June 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has repaid all amounts outstanding…
5 months ago globenewswire.com
Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib…
5 months ago globenewswire.com
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
MONTREAL, May 08, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) pharmaceutical company, announced today that its Brazilian affiliate, United Medical…
5 months ago seekingalpha.com
Knight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call Transcript
Knight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call Transcript
5 months ago globenewswire.com
Knight Therapeutics Reports First Quarter 2026 Results
Increased 2026 revenue guidance from $510 million to $525 million Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception
5 months ago globenewswire.com
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) pharmaceutical company, announced today the voting results from…
5 months ago seekingalpha.com
Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript
6 months ago globenewswire.com
Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call
MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) pharmaceutical company, will release its first quarter 2026 financial results on…
7 months ago seekingalpha.com
Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript
Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript
7 months ago globenewswire.com
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
Delivered record-high revenues, Adjusted EBITDA 1 , Adjusted EBITDA per shar e 1 since inception Generated record high cash flow from operations since inception Provides 2026 revenues guidance of…
7 months ago globenewswire.com
Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call
MONTREAL, March 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end…
7 months ago defenseworld.net
Knight Therapeutics (KHTRF) Expected to Announce Earnings on Thursday
Knight Therapeutics (OTCMKTS:KHTRF - Get Free Report) is anticipated to release its resultson Thursday, March 19th. Analysts expect Knight Therapeutics to post earnings of ($0.0029) per share and…
8 months ago globenewswire.com
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil
MONTREAL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,…
10 months ago globenewswire.com
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved…
11 months ago seekingalpha.com
Knight Therapeutics Inc. (GUD:CA) Q3 2025 Earnings Call Transcript
Knight Therapeutics Inc. ( GUD:CA ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Samira Sakhia - President, CEO & Director Arvind Utchanah - Chief Financial Officer Amal…
11 months ago globenewswire.com
Knight Therapeutics Reports Third Quarter 2025 Results
Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception Increased 2025 financial guidance
1 year ago globenewswire.com
Knight Announces Closing of US$100 Million Revolving Credit Facility
MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has…
1 year ago globenewswire.com
Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2025 financial…
1 year ago globenewswire.com
Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies
MONTREAL, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 384 on the 2025 Report on Business magazine's…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Lows On Wednesday